14:02 , Dec 11, 2017 |  BC Extra  |  Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

In a paper published in the Journal of Cell Biology, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with six adeno-associated...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers SNPs near the gene encoding estrogen receptor-a for predicting breast cancer risk in Latina women Genetic variants near the gene...
07:00 , Apr 27, 2009 |  BC Week In Review  |  Company News

Clarient, Indiana Research and Technology Corp. (IURTC) deal

Clarient received exclusive, worldwide rights to commercialize IURTC's IP covering the forkhead box A1 (FOXA1) biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. Clarient said the IP complements its...